Evidence map›Paper›PMID 27803862›Full record

ArticleInternational journal of ophthalmology2016

Clinical research of fenofibrate and spironolactone for acute central serous chorioretinopathy.

Yong Chai, Rong-Qiang Liu, Jing-Lin Yi, Ling-Hong Ye, Jing Zou, Nan Jiang, Yi Shao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yong ChaiDepartment of Ophthalmology, the First Affiliated Hosptal of Nanchang University, Jiangxi Province Clinical Ophthalmology Institute, Nanchang 330006, Jiangxi Province, China; Affiliated Eye Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Rong-Qiang LiuDepartment of Ophthalmology, the First Affiliated Hosptal of Nanchang University, Jiangxi Province Clinical Ophthalmology Institute, Nanchang 330006, Jiangxi Province, China; Postgraduate College, the Third Hospital Affiliated of Sun Yat-sen University, Guangzhou 510000, Guangdong Province, China.
Jing-Lin YiAffiliated Eye Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Ling-Hong YeDepartment of Ophthalmology, the First Affiliated Hosptal of Nanchang University, Jiangxi Province Clinical Ophthalmology Institute, Nanchang 330006, Jiangxi Province, China.
Jing ZouAffiliated Eye Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Nan JiangDepartment of Ophthalmology, the First Affiliated Hosptal of Nanchang University, Jiangxi Province Clinical Ophthalmology Institute, Nanchang 330006, Jiangxi Province, China.
Yi ShaoDepartment of Ophthalmology, the First Affiliated Hosptal of Nanchang University, Jiangxi Province Clinical Ophthalmology Institute, Nanchang 330006, Jiangxi Province, China.
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo compare the effectiveness of combined fenofibrate and spironolactone with fenofibrate alone for treatment of central serous chorioretinopathy (CSCR).

methodsTotally 60 patients (60 eyes) with a history of acute CSCR were randomed into two groups: group A with combination of fenofibrate (200 mg) and spironolactone (100 mg), and group B with only fenofibrate (200 mg). They were taken half an hour before meals and once per day for 8wk. The changes of the visual acuity, subjective symptom, ocular surface disease index (OSDI), the tear film and optical coherence tomography were observed at 2, 4, 6, and 8wk before and after treatment.

resultsThe best corrected visual acuity (BCVA, logMAR) was improved to 0.22 and 0.27 after treatment from baseline of 0.35 and 0.36 in groups A and B (

conclusionFenofibrate combined with spironolactone may have more clinical efficacy in the treatment of CSCR than fenofibrate only.

Indexed as

central serous chorioretinopathyfenofibrateoptical coherence tomographyspironolactonevision

Identifiers

PMID27803862
PMCPMC5075660
OpenAlexW2546860220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.